{"id":"radioactive-iodine-therapy","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Thyroid dysfunction"},{"rate":"5-15%","effect":"Salivary gland dysfunction"},{"rate":"5-15%","effect":"Xerostomia"},{"rate":"5-10%","effect":"Nausea and vomiting"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201225","moleculeType":"Small molecule","molecularWeight":"253.81"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The radioactive iodine is selectively taken up by the thyroid cells, where it emits radiation that kills the cancer cells. This treatment is often used for patients with thyroid cancer that has spread to other parts of the body or for patients who have a high risk of recurrence.","oneSentence":"Radioactive Iodine Therapy involves the use of radioactive iodine to destroy cancer cells in the thyroid gland.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:09.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thyroid cancer that has spread to other parts of the body"},{"name":"Thyroid cancer with a high risk of recurrence"}]},"trialDetails":[{"nctId":"NCT03244956","phase":"PHASE2","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-12-27","conditions":"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation","enrollment":40},{"nctId":"NCT00107289","phase":"PHASE2","title":"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-05","conditions":"Neuroblastoma, Pheochromocytoma","enrollment":200},{"nctId":"NCT07453225","phase":"PHASE1, PHASE2","title":"Empirical Radioactive Iodine Therapy in DTC","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04-01","conditions":"Differentiated Thyroid Cancer","enrollment":100},{"nctId":"NCT05599139","phase":"NA","title":"Iodine Uptake After a Low Iodine Diet","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2023-02-22","conditions":"Differentiated Thyroid Cancer","enrollment":25},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT06440850","phase":"PHASE2","title":"Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-15","conditions":"Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma","enrollment":21},{"nctId":"NCT04495985","phase":"","title":"CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-07-14","conditions":"Thyroid Cancer","enrollment":39},{"nctId":"NCT06853925","phase":"NA","title":"Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2025-10-02","conditions":"Thyroid Neoplasms","enrollment":88},{"nctId":"NCT06980103","phase":"NA","title":"Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer","status":"RECRUITING","sponsor":"Georgetown University","startDate":"2025-08-06","conditions":"Thyroid Cancer","enrollment":408},{"nctId":"NCT07314255","phase":"","title":"The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2025-12-18","conditions":"PTC, I-131, Trop2","enrollment":60},{"nctId":"NCT03109847","phase":"PHASE2","title":"Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-01-05","conditions":"Thyroid","enrollment":13},{"nctId":"NCT05999630","phase":"PHASE3","title":"Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-08-21","conditions":"Nasolacrimal Duct Obstruction, Thyroid Cancer","enrollment":100},{"nctId":"NCT07210502","phase":"NA","title":"Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2025-12-01","conditions":"Prostate Adenocarcinoma","enrollment":220},{"nctId":"NCT05660954","phase":"PHASE2","title":"Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-05-25","conditions":"Differentiated Thyroid Cancer","enrollment":41},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT06371339","phase":"NA","title":"Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2024-04-25","conditions":"Hyperthyroidism","enrollment":22},{"nctId":"NCT01163383","phase":"","title":"131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol","status":"AVAILABLE","sponsor":"John Maris","startDate":"","conditions":"Neuroblastoma, Childhood Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT06923826","phase":"PHASE2","title":"Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-04-15","conditions":"Salivary Gland Cancer, Thyroid Cancer","enrollment":32},{"nctId":"NCT05142904","phase":"PHASE3","title":"Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules","status":"TERMINATED","sponsor":"Rijnstate Hospital","startDate":"2021-11-17","conditions":"Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function, Thyroid Nodule; Hyperthyroidism","enrollment":40},{"nctId":"NCT04892303","phase":"PHASE1","title":"Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-03-17","conditions":"Recurrent Thyroid Cancer","enrollment":48},{"nctId":"NCT07015684","phase":"PHASE1","title":"131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-28","conditions":"Sickling Disorder Due to Hemoglobin S","enrollment":24},{"nctId":"NCT00135200","phase":"PHASE2","title":"Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2005-08","conditions":"Multiple Myeloma","enrollment":16},{"nctId":"NCT05410821","phase":"PHASE1","title":"Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-06-15","conditions":"Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma","enrollment":12},{"nctId":"NCT06464341","phase":"","title":"Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-05-04","conditions":"Breast Cancer","enrollment":583},{"nctId":"NCT02393690","phase":"PHASE2","title":"Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2015-05-04","conditions":"Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma","enrollment":60},{"nctId":"NCT06437873","phase":"","title":"Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC","status":"COMPLETED","sponsor":"Dezhou Hospital Qilu Hospital of Shandong University","startDate":"2000-01-01","conditions":"Follicular Thyroid Cancer, SEER Database Analysis","enrollment":2957},{"nctId":"NCT04354324","phase":"NA","title":"Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2020-04-20","conditions":"Papillary Thyroid Cancer","enrollment":254},{"nctId":"NCT01502917","phase":"PHASE1","title":"Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy","status":"COMPLETED","sponsor":"Y-mAbs Therapeutics","startDate":"2011-12","conditions":"Brain Cancer, Brain Stem Glioma","enrollment":50},{"nctId":"NCT05989555","phase":"","title":"Effects of Radioactive Iodine on the Immune System in Thyroid Cancer","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2024-01-01","conditions":"Thyroid Carcinoma, Nonmedullary","enrollment":30},{"nctId":"NCT04447183","phase":"PHASE2","title":"The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.","status":"UNKNOWN","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-11-23","conditions":"Differentiated Thyroid Cancer","enrollment":120},{"nctId":"NCT05643365","phase":"","title":"Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2013-01-01","conditions":"Radioactive Iodine-Induced Hypothyroidism in Graves Disease Patients","enrollment":300},{"nctId":"NCT05869474","phase":"NA","title":"Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2023-08-01","conditions":"Metastatic Pancreatic Cancer","enrollment":206},{"nctId":"NCT05063357","phase":"PHASE1","title":"131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma","status":"WITHDRAWN","sponsor":"Y-mAbs Therapeutics","startDate":"2022-03","conditions":"DIPG","enrollment":""},{"nctId":"NCT00534196","phase":"","title":"Implant Radiation Therapy Using Radioactive Iodine in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2005-07","conditions":"Prostate Cancer","enrollment":6927},{"nctId":"NCT02303444","phase":"","title":"An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-04-08","conditions":"Thyroid Neoplasms","enrollment":667},{"nctId":"NCT00788307","phase":"PHASE1","title":"Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2008-11-03","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT00079417","phase":"PHASE3","title":"Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-12-26","conditions":"Intraocular Retinoblastoma","enrollment":28},{"nctId":"NCT03506048","phase":"PHASE2","title":"Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2019-01-16","conditions":"Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma","enrollment":4},{"nctId":"NCT05468554","phase":"PHASE3","title":"Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2022-11-01","conditions":"Thyroid Cancer","enrollment":160},{"nctId":"NCT05512715","phase":"PHASE4","title":"LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism","status":"COMPLETED","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","startDate":"2021-01-10","conditions":"Hyperthyroidism/Thyrotoxicosis","enrollment":90},{"nctId":"NCT04009863","phase":"NA","title":"HIFU Ablation vs Fixed-dose RAI-131 Therapy in Moderate-sized Non-toxic MNG","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-04-01","conditions":"Non Toxic Multinodular Goiter, High Intensity Focused Ultrasound, RAI","enrollment":156},{"nctId":"NCT01444209","phase":"PHASE2","title":"Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-09-30","conditions":"Pituitary Macroadenoma","enrollment":2},{"nctId":"NCT01396733","phase":"PHASE2","title":"Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer","status":"WITHDRAWN","sponsor":"Asan Medical Center","startDate":"2011-04","conditions":"Thyroid, Cancer","enrollment":""},{"nctId":"NCT04663451","phase":"","title":"An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2020-09-11","conditions":"Nodule Solitary Thyroid, Toxic Multinodular Goiter, Radioactive Iodine-Induced Hypothyroidism","enrollment":150},{"nctId":"NCT04135573","phase":"","title":"The Relationship Between NK Cell and Graves' Disease","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2018-10-15","conditions":"Graves Disease","enrollment":200},{"nctId":"NCT04554680","phase":"PHASE2","title":"Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2020-12-30","conditions":"Thyroid Cancer","enrollment":5},{"nctId":"NCT04715828","phase":"","title":"Impact of Ionizing Treatment on the Nuclear Structure of Human Spermatozoa.","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2018-01-01","conditions":"Sperm Preservation, Irradiated Semen","enrollment":200},{"nctId":"NCT04332770","phase":"","title":"Biosignals by Wearable Devices in Hypothyroidism","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2019-06-14","conditions":"Hypothyroidism","enrollment":45},{"nctId":"NCT02558205","phase":"","title":"Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2015-07","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01441154","phase":"","title":"Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-09-20","conditions":"Malignant Struma Ovarii, Papillary Thyroid Cancer, Hurthle Cell Thyroid Cancer","enrollment":16},{"nctId":"NCT00668811","phase":"PHASE2","title":"Sutent Adjunctive Treatment of Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2008-04","conditions":"Papillary Thyroid Cancer, Follicular Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":23},{"nctId":"NCT04396158","phase":"NA","title":"Effect of Radioiodine Therapy on Ovarian Reserve in Female Patients With Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-06-15","conditions":"Ovarian Insufficiency, Radiation Exposure","enrollment":38},{"nctId":"NCT04180007","phase":"PHASE2","title":"Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2019-04-10","conditions":"Thyroid, Metastasis, Apatinib","enrollment":10},{"nctId":"NCT01950260","phase":"PHASE2, PHASE3","title":"Early Levothyroxine Post Radioactive Iodine","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-09","conditions":"Graves' Disease","enrollment":61},{"nctId":"NCT01843062","phase":"PHASE3","title":"Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-08-27","conditions":"Differentiated Thyroid Cancer","enrollment":233},{"nctId":"NCT04031638","phase":"","title":"Thyroid Cancer Database","status":"UNKNOWN","sponsor":"Centre Georges Francois Leclerc","startDate":"2000-01-01","conditions":"Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment","enrollment":2300},{"nctId":"NCT02390934","phase":"PHASE2","title":"Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2014-10-01","conditions":"Thyroid Cancer","enrollment":13},{"nctId":"NCT02021929","phase":"PHASE2","title":"Sorafenib for Hepatopulmonary Syndrome","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2014-03","conditions":"Hepatopulmonary Syndrome","enrollment":28},{"nctId":"NCT00104871","phase":"PHASE2","title":"Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12","conditions":"Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer","enrollment":24},{"nctId":"NCT00085293","phase":"PHASE2","title":"Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-05","conditions":"Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer","enrollment":12},{"nctId":"NCT01025453","phase":"PHASE2","title":"Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-12-01","conditions":"Thyroid Cancer","enrollment":37},{"nctId":"NCT00115895","phase":"PHASE3","title":"The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy","status":"UNKNOWN","sponsor":"University of Helsinki","startDate":"2000-01","conditions":"Thyroid Neoplasms","enrollment":160},{"nctId":"NCT01269749","phase":"PHASE2","title":"Radioactive Iodide Therapy for Pediatric Graves' Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-10","conditions":"Graves' Disease","enrollment":19},{"nctId":"NCT01536561","phase":"PHASE1","title":"Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1990-04-24","conditions":"Lymphoma, Non-Hodgkin","enrollment":59},{"nctId":"NCT00729157","phase":"PHASE2","title":"Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08","conditions":"Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma","enrollment":41},{"nctId":"NCT00559949","phase":"PHASE2","title":"Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12","conditions":"Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma","enrollment":39},{"nctId":"NCT01389076","phase":"PHASE2","title":"Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2011-07","conditions":"Follicular Lymphoma","enrollment":22},{"nctId":"NCT02418247","phase":"PHASE2, PHASE3","title":"Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2013-05","conditions":"Thyroid Neoplasms","enrollment":556},{"nctId":"NCT01224821","phase":"PHASE2","title":"Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-12","conditions":"Lymphoma, Non-Hodgkin","enrollment":47},{"nctId":"NCT01083550","phase":"PHASE2, PHASE3","title":"Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-02","conditions":"Thyroid Cancer","enrollment":74},{"nctId":"NCT01286753","phase":"PHASE2","title":"A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06","conditions":"Neoplasms","enrollment":51},{"nctId":"NCT01360177","phase":"NA","title":"Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2010-07","conditions":"Breast Cancer, Metastatic Breast Cancer","enrollment":""},{"nctId":"NCT01994200","phase":"PHASE1, PHASE2","title":"Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients","status":"WITHDRAWN","sponsor":"Jewish General Hospital","startDate":"2014-09","conditions":"Thyroid Cancer","enrollment":""},{"nctId":"NCT01413113","phase":"PHASE1","title":"Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2011-12","conditions":"Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer","enrollment":6},{"nctId":"NCT00450827","phase":"PHASE1","title":"Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-08","conditions":"Neuroblastoma","enrollment":25},{"nctId":"NCT02499471","phase":"NA","title":"Brown Adipose Tissue Activity and Thyroid Hormone","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2012-03","conditions":"Hypothyroidism, Hyperthyroidism, Obesity","enrollment":12},{"nctId":"NCT02107794","phase":"NA","title":"Shared Decision Making in Graves Disease - Graves Disease (GD) Choice","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-12","conditions":"Graves' Disease, Thyroid Disease, Hyperthyroidism","enrollment":93},{"nctId":"NCT02238613","phase":"NA","title":"Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer","status":"UNKNOWN","sponsor":"307 Hospital of PLA","startDate":"2014-08","conditions":"Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Ampullary Carcinoma","enrollment":140},{"nctId":"NCT00098813","phase":"PHASE2","title":"Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10","conditions":"Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer","enrollment":20},{"nctId":"NCT00718770","phase":"EARLY_PHASE1","title":"A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-11","conditions":"Thyroid Cancer","enrollment":10},{"nctId":"NCT00027768","phase":"PHASE3","title":"Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer","status":"UNKNOWN","sponsor":"National Medical Research Council (NMRC), Singapore","startDate":"2001-06","conditions":"Liver Cancer","enrollment":300},{"nctId":"NCT01174017","phase":"PHASE3","title":"Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2010-09","conditions":"Prostate Cancer","enrollment":41},{"nctId":"NCT01744769","phase":"","title":"Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2012-07","conditions":"Hypothyroidism","enrollment":80},{"nctId":"NCT01717729","phase":"PHASE3","title":"Hepatocellular Carcinoma Treated With Iodine-125 Implantation","status":"COMPLETED","sponsor":"The Second People's Hospital of GuangDong Province","startDate":"2000-01","conditions":"Liver Carcinoma","enrollment":136},{"nctId":"NCT01579344","phase":"NA","title":"Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma","status":"UNKNOWN","sponsor":"Fabricio Lopes da Fonseca","startDate":"2012-01","conditions":"Lacrimal Apparatus Disease","enrollment":100},{"nctId":"NCT00902122","phase":"PHASE4","title":"rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors","status":"UNKNOWN","sponsor":"Shenzhen SiBiono GeneTech Co.,Ltd","startDate":"2009-05","conditions":"Advanced Malignant Thyroid Tumors","enrollment":600},{"nctId":"NCT00475332","phase":"PHASE2","title":"Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar","status":"TERMINATED","sponsor":"University of Florida","startDate":"2007-09","conditions":"Non-Hodgkin's Lymphoma, Follicular Lymphoma","enrollment":2},{"nctId":"NCT00509483","phase":"NA","title":"Three-Year Follow-up of Radioiodine Therapy for Goitre","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2002-01","conditions":"Tratment of Multinodular Goitre","enrollment":40},{"nctId":"NCT00749697","phase":"NA","title":"Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2008-05","conditions":"Thyroid Carcinoma, Metastatic Sites Lung Bone Nodal","enrollment":10},{"nctId":"NCT00525122","phase":"","title":"Treatment of M.Graves With Radioactive Iodine: Follow-up Study","status":"UNKNOWN","sponsor":"Medisch Centrum Rijnmond-Zuid, Netherlands","startDate":"2007-09","conditions":"Hyperthyroidism","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1213,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Radioactive Iodine Therapy","genericName":"Radioactive Iodine Therapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Radioactive Iodine Therapy involves the use of radioactive iodine to destroy cancer cells in the thyroid gland. Used for Thyroid cancer that has spread to other parts of the body, Thyroid cancer with a high risk of recurrence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}